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Abstract
Coronavirus disease 2019 (COVID-19), the illness caused by the SARS-CoV-2 virus, is rapidly spreading 
throughout the world. Hospitals and healthcare providers are preparing for the anticipated surge in 
critically ill patients but few are wholly equipped to manage this new disease. We all must do our part to 
prepare our patients, clinics, and hospitals for the drastic changes necessary to mitigate the spread of 
SARS-CoV-2 or we risk overwhelming the capacity of our healthcare system. The goals of this document 
are to provide data on what is currently known about COVID-19, and how it may impact hepatologists 
and liver transplant providers and their patients. Our aim is to provide a template for the development 
of clinical recommendations and policies to mitigate the impact of the COVID-19 pandemic on liver 
patients and healthcare providers.
An earlier version of this document was first posted online on March 23, 2020 at 
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Overview and Rationale
Coronavirus disease 2019 (COVID-19), the illness caused by the SARS-CoV-2 virus, is rapidly spreading 
throughout the world.(1) Hospitals and healthcare providers across the United States are preparing for 
the anticipated surge in critically ill patients but few are wholly equipped to manage this new disease. 
Nonetheless, we all must do our part to prepare our patients, clinics, and hospitals for the drastic 
changes necessary to mitigate the spread of SARS-CoV-2 or we risk overwhelming the capacity of our 
healthcare system.(2) In addition, we must continue to manage the care of our patients with liver 
disease and our liver transplant recipients where unique logistical and pharmacological issues will arise. 
According to the Centers for Disease Control and Prevention (CDC), patients >65 years old, patients with 
cardiovascular disease, diabetes mellitus, morbid obesity, chronic obstructive pulmonary disease, or 
liver disease are at higher risk for severe COVID-19.(3) However, while the CDC considers those with 
liver disease to be at increased risk, it is unclear if patients with cirrhosis, those with autoimmune 
hepatitis on immunosuppressive medications, and pretransplant and posttransplant patients on 
immunosuppressant therapy are at increased risk for severe COVID-19. Given the extraordinary amount 
of rapidly emerging data on COVID-19, it is difficult for any single clinician to stay abreast of the latest 
information. The goals of this document are to provide data on what is currently known about COVID-
19, and how it may impact hepatologists and liver transplant providers and their patients. Our aim is to 
provide a template for the development of clinical recommendations and policies to mitigate the impact 
of the COVID-19 pandemic on liver patients and healthcare providers. Considering that SARS-CoV-2 can 
be transmitted from asymptomatic individuals, including children, and it can be detected in stool after 
viral clearance from pharyngeal samples,(4–6) these recommendations have been created to protect 
our patients, communities, and healthcare workers. Data from China, Italy, and Spain are staggering 
with reports from Italy indicating that up to 20% of healthcare workers who are taking care of patients 
with COVID-19 may become infected.(7) If we do not contain the spread of SARS-CoV-2 quickly, our 
healthcare system’s capacity will be overwhelmed, including insufficient availability of intensive care 
unit (ICU) beds, ventilators, and healthcare workers.
Effects of SARS-CoV-2 on the Liver and Evaluation of COVID-19 Patients with Elevated Liver 
Biochemistries
The novel coronavirus SARS-CoV-2 is most similar to the beta-coronaviruses, SARS-CoV and MERS-CoV, 
the causative agents of the SARS outbreak in 2002-2003 and the MERS outbreak beginning in 2012, 
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RNA-dependent RNA polymerase. SARS-CoV-2 binds to and is internalized into target cells through 
angiotensin-converting enzyme 2 (ACE2), which acts as a functional receptor.(8,9) ACE2 is present in 
biliary and liver epithelial cells; therefore, the liver is a potential target for infection.(10) The incidence 
of elevated serum liver biochemistries in hospitalized patients with COVID-19 ranges from 14% to 
53%.(1,11–15) AST and ALT are primarily elevated in COVID-19, generally 1-2 times the upper limit of 
normal (ULN), with normal to modestly elevated total bilirubin levels early in the disease process. Liver 
injury occurs more commonly in severe COVID-19 cases than in mild cases, and rare cases of severe 
acute hepatitis have been described.(11,15,16) Liver injury in mild COVID-19 cases is usually transient 
and does not require specific treatment.(15) In addition to other markers of disease severity such as 
lymphopenia and D-dimer, low serum albumin on hospital admission is a marker of COVID-19 
severity.(14,17,18)
Severe COVID-19 is uncommon in children.(19,20) In the rare cases of severe pediatric COVID-19, 
increases in ALT or AST, when present, are usually mild (<2x ULN).(19) Data from Bergamo, a major site 
of COVID-19 in Italy, showed no increase in hospitalization among >300 children followed for liver 
transplantation, autoimmune hepatitis, or hepatoblastoma.(20) In this report, 3 of 13 hospitalized 
children following liver transplantation or receiving chemotherapy for hepatoblastoma tested positive 
for SARS-CoV-2 and none developed clinical pulmonary disease.(20)
Liver histologic assessment has been limited but thus far is nonspecific and ranges from moderate 
microvesicular steatosis with mild, mixed lobular and portal activity to focal necrosis.(21,22) Elevated 
liver biochemistries may reflect a direct virus-induced cytopathic effect and/or immune damage from 
the provoked inflammatory response.(12,23) Therapeutic agents used to manage symptomatic COVID-
19 may be hepatotoxic, including remdesivir and tocilizumab. Less common causes of elevated liver 
biochemistries include chloroquine, hydroxychloroquine, and azithromycin.
It is unknown whether patients with chronic liver disease, especially viral hepatitis B and/or C, are more 
susceptible to liver damage from SARS-CoV-2, as was the case with SARS-CoV.(14) It is also unknown 
whether SARS-CoV-2 infection exacerbates cholestasis in those with underlying cholestatic liver disease 
such as primary biliary cholangitis or primary sclerosing cholangitis or with underlying cirrhosis.(15) 
Emerging data suggest that patients with nonalcoholic fatty liver disease (NAFLD) may be at higher risk 
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factors such as cardiovascular disease, diabetes mellitus, and obesity, which are known to be associated 
with COVID-19 severity.(25)
It will be difficult to differentiate whether increases in liver biochemistries are due to SARS-CoV-2 
infection itself; its complications, including myositis (particularly with AST>ALT), cytokine release 
syndrome, ischemia/hypotension; or a drug-induced liver injury.(15,21) An approach to evaluating the 
patient with COVID-19 and elevated liver biochemistries is shown in Figure 1.
Recommendations
 Patients with cirrhosis, those with autoimmune hepatitis on immunosuppressive medications, 
and posttransplant patients on immunosuppressant therapy should be considered to be at 
increased risk for severe COVID-19 and should be prioritized for testing until further data 
become available.
 Consider etiologies unrelated to COVID-19, including other viruses such as hepatitis A, B and C, 
when assessing patients with COVID-19 and elevated liver biochemistries.
 To limit unnecessary transport of patients with COVID-19, ultrasound or other advanced imaging 
(e.g., MRI/MRCP) should be avoided unless it is likely to change management, e.g., clinical 
suspicion for biliary obstruction or venous thrombosis.
 Consider other causes of elevated liver biochemistries, including myositis (particularly when 
AST>ALT), cardiac injury, ischemia, and cytokine release syndrome.
 The presence of abnormal liver biochemistries should not be a contraindication to using 
investigational or off-label therapeutics for COVID-19 (e.g., remdesivir, tocilizumab, chloroquine, 
hydroxychloroquine), although AST or ALT levels >5x ULN may exclude patients from 
consideration of some investigational agents.
 Regular monitoring of liver biochemistries should be performed in all hospitalized COVID-19 
patients, particularly those treated with remdesivir or tocilizumab, regardless of baseline values.
 In patients with autoimmune hepatitis or liver transplant recipients with active COVID-19 and 
elevated liver biochemistries, do not presume disease flare or acute cellular rejection without 
biopsy confirmation.
 Evaluate all children with elevated AST or ALT for underlying liver diseases and coexisting 
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 Follow guidance in your clinical study protocol and/or by the Food and Drug Administration 
(FDA) for monitoring of liver biochemistries and discontinuation of study drug used to treat 
COVID-19.
Stable Outpatients with Liver Disease and/or Hepatocellular Carcinoma
Information is limited regarding the effects of SARS-CoV-2 in patients with chronic liver disease. Data 
from the CDC on 122,653 COVID-19 cases including 7,162 (5.8%) with data on underlying health 
conditions, showed that approximately one third of these patients (37.6%) had at least one underlying 
condition or risk factor for severe outcomes.(26) Among these patients with underlying conditions, only 
41 patients (0.6%) had chronic liver disease, including 7 who required ICU admission.(26)
Both immunocompetent and immunosuppressed patients can contribute to SARS-CoV-2 spread even if 
they are asymptomatic.(27) Children are less likely to become ill from SARS-CoV-2 infection but can still 
contribute to spread of the virus.(19) There is no evidence that patients with stable chronic liver disease 
due to hepatitis B and/or C, or cholestatic syndromes such as primary biliary cholangitis or primary 
sclerosing cholangitis have increased susceptibility to SARS-CoV-2 infection.(15)
The effect of COVID-19 in patients with hepatocellular carcinoma (HCC) is not known. A case series 
reported an association between worse COVID-19 outcomes and a history of non-hepatic types of 
cancer.(28) Those who underwent recent chemotherapy had an even higher risk of severe COVID-19, 
but the series also included those without recent chemotherapy.(28) It is unknown whether patients 
with HCC are at increased risk for severe COVID-19 by virtue of their malignancy. The slow median 
doubling time of HCC supports a rationale of a short delay in radiological surveillance given the 
challenges many centers are currently facing with COVID-19.(29)
Recommendations
 The CDC has provided broad and comprehensive recommendations to limit face-to-face visits, 
optimize supply of personal protective equipment (PPE), clean and disinfect rooms or areas 
visited by individuals with suspected or confirmed COVID-19, and monitor healthcare workers 
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o Consider seeing in person only new adult and pediatric patients with urgent issues and 
clinically significant liver disease (e.g., jaundice, elevated ALT or AST >500 U/L, recent 
onset of hepatic decompensation).
 Continue treatment for hepatitis B and hepatitis C if already on treatment.
 Proceed with treatment of hepatitis B and C in patients without COVID-19 as clinically 
warranted. The logistics of monitoring patients during the pandemic should be weighed against 
the urgency of treatment.
 Initiating treatment of hepatitis B in a patient with COVID-19 is not routinely warranted but 
should be considered if there is clinical suspicion of a hepatitis B flare.
 Initiating treatment of hepatitis C in a patient with COVID-19 is not routinely warranted.
 Continue monitoring in those on or off therapy for HCC and continue surveillance in those at risk 
for HCC (cirrhosis, chronic hepatitis B) as close to schedule as circumstances allow, although an 
arbitrary delay of 2 months is reasonable.
o Discuss the risks and benefits of delaying surveillance with the patient and document 
the discussion.
 Review images of new referrals for patients with liver masses in tumor board or with expert 
radiologists in virtual multidisciplinary conference prior to scheduling an in-person visit.
 Consider virtual patient visits to discuss diagnosis and management of HCC and other liver 
tumors.
 Proceed with HCC treatments when able rather than delaying them due to the pandemic. 
Patients with Decompensated Cirrhosis, Liver Transplant Evaluations, and Patients on the Liver 
Transplant Waiting List
Information is limited regarding the effects of SARS-CoV-2 infection in patients with decompensated 
cirrhosis or those awaiting liver transplantation. The complex decision making involved in whether or 
not to proceed with transplantation is now significantly more challenging due to the COVID-19 
pandemic. It is essential that transplant centers continuously assess their local situation and its impact 
on patients awaiting transplantation. Some transplant centers may decide that individual candidates 
should not receive organ offers at this time. Special consideration could be given to wait-listed patients 
with high model for end-stage liver disease (MELD) scores or HCC based on their risk of drop-out and 
disease progression. A reduction in organ recovery is expected because of COVID-19-related limitations 
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transmission. These factors will have a significant impact on the transplant waiting list resulting in 
increased waiting times. Risk stratification is important to identify patients who need to be evaluated for 
transplantation or complete their evaluation during the COVID-19 pandemic, including patients with 
high MELD scores, risk of decompensation, or tumor progression.
Recommendations
 Limit the number of patients coming to clinic for transplant evaluations. 
o Consider evaluating only patients with HCC or those patients with severe disease and 
high MELD scores who are likely to benefit from immediate liver transplant listing.
 Develop a policy to decide which listed patients need to be seen in person.
 Consider telemedicine alternatives in place of outreach clinics.
 Obtain labs and imaging only as clinically necessary. 
o Patients should not be asked to update labs simply to update their MELD score. Recent 
Organ Procurement and Transplantation Network (OPTN) policy changes provide 
guidance on how to maintain candidate MELD when updated lab results are not 
obtained.(31)
 Ensure that patients have refills available for essential medications. Provide prescriptions for 90-
day supplies instead of 30-day supplies. Many insurance companies are waiving early 
medication refill limits. Consider using medication delivery services.
 Consider instructing patients to avoid attending in-person community recovery support 
meetings such as Alcoholics Anonymous and provide alternative telephone or online resources. 
 Advise patients not to travel during the COVID-19 pandemic.
 Consider providing documentation to patients, providers, and organ procurement teams to ease 
essential travel where travel restriction policies are in place.
 Have a low threshold for admitting patients on the transplant waiting list who are diagnosed 
with COVID-19.
 Consider using specific screening facilities and a “COVID-19-free” path through the hospital for 
transplantation candidates.
 Conduct patient transplant education and social work, dietitian, and financial consultations by 
video conference, telemedicine, or telephone whenever possible.
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o Consider developing internet-based education sessions for patients and family members 
that can be deployed either by in-room computers or at home prior to patient 
evaluation.
Liver Transplantation, Resource Utilization, and Ethical Considerations
Resource utilization and ethical considerations are inherently tied to liver transplantation. This is a 
critical and challenging area for which protocols and policies need to be carefully considered and 
developed. There is no over-arching policy that can or should be applied to every transplant center; 
these issues will need to be discussed and developed locally (Table 1). Although the Centers for 
Medicare and Medicaid Services (CMS) recommends limiting all non-essential planned surgeries and 
procedures until further notice, they specifically exclude transplant surgery from this recommendation 
and categorize transplant surgery as Tier 3b (“do not postpone”).(32)
Insufficient data regarding viral transmission of SARS-CoV-2 from organ donors are available at this time, 
but currently most Organ Procurement Organizations are testing donors for SARS-CoV-2 RNA, and those 
who test positive are medically ineligible for organ donation.(33) Based on center capability, testing for 
SARS-CoV-2 should be considered in all recipients prior to transplant; however, the capacity to test 
recipients shortly before proceeding with transplant may be limited and can add additional logistical 
hurdles. There is a significant false negative rate and transplant programs should consider symptoms of 
COVID-19 to be strongly suggestive of infection despite negative testing. Transplantation in SARS-CoV-2-
positive recipients is currently not recommended.
Recommendations
 Develop a hospital-specific policy for organ acceptance. 
o Ensure hospital administrators are aware of the CMS Tier 3b designation for transplant 
surgery (“Do not postpone”).(32)
o Consider recipient age and comorbidities prior to organ acceptance. 
o Consider resource utilization including ICU beds, ventilators, PPE and supply of blood 
products (especially platelets and type-specific packed red cells) in the decision to 
proceed with liver transplantation. 
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 Consider notifying patients that the COVID-19 pandemic may impact their waiting time on the 
transplant list. 
 Notify patients that family and visitor access may be limited or prohibited during their hospital 
stay.
 Screen potential donors for exposure and clinical symptoms/fever compatible with COVID-19 
(regardless of test results or availability).(34)
o Alternatives to PCR-based testing such as chest radiography may also be considered.
 Screen potential recipients with an acceptable organ offer for COVID-19 symptoms/fever before 
they are called in from home for transplantation.
 When an organ offer becomes available, call in to the hospital potential transplant recipients at 
the latest possible time to minimize exposure to the hospital environment. 
 Consider accepting only grafts with a low risk of delayed graft function to minimize 
complications and postoperative lengths of stay.
 Consider testing recipients and donors for SARS-CoV-2 before transplantation, if testing is 
available.
o Consider the risk of false negatives, disease prevalence, and testing turnaround time in 
your area.
o Review as much donor history as possible for fever, respiratory symptoms, and 
radiographic findings.
 Consider having backup transplant recipients wait at home or away from the transplant center. 
 Consider suspending living donor liver transplant programs during the pandemic, except for 
pediatric patients with acute liver failure.(34)
 See the latest updates regarding COVID-19 related OPTN policy changes.(31)
 An approach to liver transplant organ offers is shown in Figure 2.
Post-Liver-Transplant Patients
Data suggest that the immune response may be the main driver for pulmonary injury due to COVID-19 
and that immunosuppression may be protective.(13,20) Posttransplant immunosuppression was not a 
risk factor for mortality associated with SARS (2002-2003) or MERS (2012-present).(20) It is too early to 
know if posttransplant patients are at greater risk for more severe COVID-19; however, 
immunosuppressed patients are considered to be at higher risk for severe illness from COVID-19.(25) 
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Recommendations
 Do not reduce immunosuppression or stop mycophenolate for asymptomatic posttransplant 
patients without known COVID-19.
 Emphasize prevention measures posttransplant patients already know well: frequent hand 
washing, cleaning frequently touched surfaces, staying away from large crowds, staying away 
from individuals who are ill, etc.
 Advise patients not to travel during the COVID-19 pandemic.(34)
 Minimize in-person visits for posttransplant patients by more frequent telephone 
communication and telemedicine.
 Consider advocating for telework options, appropriate excuses from work or leaves of absence 
for posttransplant patients and their primary caregivers.
Management of Patients on Immunosuppressive Agents
The effects of immunosuppression on COVID-19 are not well established. Rapid pulmonary deterioration 
in COVID-19 is due to a systemic/pulmonary inflammatory response associated with increased serum IL-
6, IL-8 and TNF- levels.(36) The potential role of corticosteroids for the prevention of progression of 
mild COVID-19 to severe pneumonia is unknown. The World Health Organization recommends avoiding 
corticosteroids for treatment of COVID-19 unless indicated for another therapeutic purpose.(37) 
Reducing the dosage or stopping immunosuppressants may cause a flare in a patient with autoimmune 
hepatitis or precipitate acute rejection in a liver transplant recipient.
Recommendations
 In immunosuppressed liver disease patients without COVID-19:
o Do not make anticipatory adjustments to current immunosuppressive drugs or dosages.
 In immunosuppressed liver disease patients with COVID-19:
o Consider minimizing the dosage of high-dose prednisone but maintain a sufficient 
dosage to avoid adrenal insufficiency.
o Consider reducing azathioprine or mycophenolate dosages, especially in the setting of 
lymphopenia, fever, or worsening pneumonia attributed to COVID-19.
o Consider reducing but not stopping daily calcineurin inhibitor dosage, especially in the 
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o An approach to managing liver transplant recipients with COVID-19 is shown in Figure 3.
 Initiate immunosuppressive therapy in patients with liver disease with or without COVID-19 who 
have strong indications for treatment (e.g., autoimmune hepatitis, graft rejection).
 In patients with COVID-19, use caution in initiating prednisone, prednisolone, or other 
immunosuppressive therapy where the potential benefit might be outweighed by the risks (e.g., 
alcohol-associated hepatitis).
Inpatients
Healthcare workers and other hospital staff are at risk for COVID-19.(7) Healthcare workers with SARS-
CoV-2 may spread the virus to patients and to each other, and should remain away from in-person work 
until approved to return by local health authorities. Minimizing interactions among healthcare workers 
and between healthcare workers and patients is critical to reducing the spread of SARS-CoV-2. 
Minimizing the transport of patients within and between healthcare facilities could reduce the spread of 
SARS-CoV-2.
Recommendations
 Conduct medical and surgical transplant rounds with the minimum number of personnel needed 
to provide care at a given time.
 Limit the number of team members who enter a patient’s room for patient examinations and 
encounters.
 Limit the personnel permitted to enter patient rooms to the minimum needed for the 
performance of consultative care.
 Discourage in-person multidisciplinary rounds with dietary, pharmacy, social work, and care 
coordination staff.
 Consider developing a policy for review and triage of hospital inpatient transfers. For example, 
consider accepting for transfer only patients with acute liver failure or those in need of urgent 
liver transplant evaluation during their hospital stay.
o Consider accepting for transfer only other liver patients with a unique need for inpatient 
interventions at the transplant center.
 Consider evaluating patients with liver disease for COVID-19 if they develop new onset 
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 Have a low threshold for aggressive airway management in COVID-19 patients with underlying 
pulmonary diseases such as hepatic hydrothorax, portopulmonary hypertension, or 
hepatopulmonary syndrome.
 Perform a needs assessment prior to patient discharge to determine whether the patient can 
have follow-up encounters by phone or telemedicine and encourage early monitoring by these 
means to reduce early postdischarge, in-person visits.
o Consider home health or visiting nurse services for frequent blood draws needed after 
posttransplant hospital discharge.
Medication Management of Patients with COVID-19 and Potential Drug-Drug Interactions
There currently are no FDA-approved therapies to prevent or treat COVID-19 infection. Many 
investigational or off-label therapeutics for COVID-19 may be hepatotoxic (Table 2). An open-label, 
randomized, controlled trial of lopinavir-ritonavir vs. standard of care in adults hospitalized with severe 
COVID-19 showed no clinical benefit.(38) Treatment was stopped early in some patients taking lopinavir-
ritonavir due to adverse events. Ritonavir is a potent inhibitor of CYP3A4, which is involved in the 
metabolism of calcineurin inhibitors, sirolimus, and everolimus. The use of ritonavir requires a reduction 
in the tacrolimus dosage to 1/20-1/50 of baseline due to this drug-drug interaction. 
Remdesivir is a nucleotide analogue with demonstrated activity against SARS-CoV and MERS-CoV in 
cultured cells, mice and non-human primates, and more recently against SARS-CoV-2 in human cell 
lines.(39,40) Remdesivir is being tested in hospitalized patients with moderate to severe COVID-19 in 
randomized controlled trials and data from compassionate use have reported promising results.(41–43) 
Drugs that target the IL-6 receptor are being tested only in hospitalized patients with moderate to 
severe COVID-19.
Hydroxychloroquine (an analogue of chloroquine with a better safety profile) has been shown to have 
anti-SARS-CoV-2 activity in vitro.(44) A single-arm study from France of 20 patients with COVID-19 who 
were treated with hydroxychloroquine with or without azithromycin compared to 16 nonrandomized 
controls reported negative nasopharyngeal swabs for SARS-CoV-2 PCR in 70% of the treated group 
compared to 12.5% of the controls.(45) A separate study from France reported that the combination of 
hydroxychloroquine and azithromycin was not associated with clinical recovery or viral clearance and 4 
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The CDC recently issued a warning about the danger of using nonpharmaceutical chloroquine 
phosphate, a commercially available chemical for aquarium use, to treat or prevent COVID-19.(47) One 
individual died after using nonpharmaceutical chloroquine and another became critically ill with 
gastrointestinal symptoms and cardiac conduction abnormalities.
Convalescent plasma transfusion holds promise for treating critically ill patients with COVID-19.(48,49) 
The FDA recently announced that it is facilitating access to convalescent plasma for patients with serious 
COVID-19 through its emergency Investigational New Drug application process.(50)
Treatment with ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) results in upregulation 
of ACE2, the target for SARS-CoV-2 entry into cells.(51) Increased ACE2 expression theoretically 
facilitates infection with SARS-CoV-2. Animal studies suggest that ACEIs and ARBs may protect against 
serious lung complications from SARS-CoV, but to date there are no data in SARS-CoV-2 or in 
humans.(52) The Council on Hypertension of the European Society of Cardiology highlighted the lack of 
evidence demonstrating harmful effects of ACEIs and ARBs in the setting of COVID-19 and recommends 
that patients should continue with their usual antihypertensive therapy, including ACEIs and ARBs.(53)
Recommendations
 Monitor studies of antiviral and immunomodulatory approaches to COVID-19 at National 
Institutes of Health’s (NIH) clinicaltrials.gov.
 The available evidence does not currently support the use of lopinavir-ritonavir for the 
treatment of COVID-19.
 Hydroxychloroquine with or without azithromycin is not routinely recommended and may be 
associated with serious adverse events such as prolongation of the QT interval.
 Patients receiving ACEIs and ARBs should remain on them even in the setting of COVID-19.
 Acetaminophen at a daily dosage of 2 g/d is the preferred analgesic and anti-pyretic for 
patients with known or suspected COVID-19.
 NSAIDS may also be used or continued as needed.(54)
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Procedures
There is potential for fecal-oral SARS-CoV-2 transmission,(1,4,6,23,43) and the virus is detected in 
saliva.(1,23,56) Multiple societies have strongly recommended rescheduling non-urgent procedures. The 
Joint Gastroenterology Societies recommend to “strongly consider rescheduling non-urgent endoscopic 
procedures”, and CMS, the US Surgeon General, and the American College of Surgeons recommend 
postponing elective surgeries.(32,57–59)
Endoscopic procedures should be considered aerosol-generating.(60) Non-urgent endoscopic 
procedures should be rescheduled to reduce the risk of disease transmission from asymptomatic 
patients, reduce the use of PPE, and reduce hospital admissions.(60) To further limit disease 
transmission, the Joint Gastroenterology Societies and the American Gastroenterological Association 
recommend healthcare workers involved with endoscopy wear a full set of PPE, including N95 masks 
and double gloves.(61,62)
Recommendations
 Cancel all elective/non-urgent procedures (e.g., endoscopy, liver biopsy, transient 
elastography).(60)
 Consider, in the interim, primary prophylaxis with beta blocker therapy instead of screening 
endoscopy in patients with clinically significant portal hypertension or high risk of 
decompensation.
 Some procedures may need to be performed, e.g., liver biopsy to rule out rejection or diagnose 
autoimmune hepatitis, therapeutic paracentesis, transjugular intrahepatic portosystemic shunt 
and/or endoscopy for variceal bleeding, follow-up band ligation in those with recent variceal 
bleeding, urgent biliary procedures for symptomatic disease such as cholangitis and sepsis 
(interventional radiology or endoscopic).
Research
During this unprecedented time, much of clinical and basic science research not directly related to 
COVID-19 has come to a standstill. Due to quarantine-related travel restrictions and potential supply 
chain interruptions, the FDA and NIH have posted guidance documents to advise on the conduct of 
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Recommendations
 Limit clinical trial activity to essential clinical trials, defined as those that enroll or follow patients 
with life-threatening or serious conditions for which participation in the clinical trial holds out 
the clear prospect of directly benefiting the patient. Patients already enrolled in clinical trials 
who are undergoing safety and efficacy assessments fall within this definition.
o Continue in-person research visits for participants already enrolled in essential clinical 
trials if required for patient safety and/or participation in the clinical trial is an integral 
part of the patient’s treatment plan.
o The study physician – in consultation with the study team, the patient’s physician, the 
patient, and the patient’s family – should carefully assess the necessity and risks of an 
in-person visit.
 Do not initiate new clinical trials at this time unless meeting the definition of an essential clinical 
trial.
 Strongly consider not enrolling new research participants into existing clinical trials unless 
meeting the definition of an essential clinical trial.
o Postpone all other in-person clinical research visits.
 Research staff should make efforts to use alternative methods to conduct research visits or 
perform testing such as check-ins with participants by phone and/or performing research-
related lab testing at lab testing centers if feasible.
 Research staff should work remotely, unless their presence is required for the safe conduct of 
the trial.
 Discuss options for conducting telehealth study visits with clinical research organizations and 
study sponsors.
 Principal investigators should notify commercial sponsors that opening new nonessential clinical 
trials and enrolling subjects into ongoing “non-essential” clinical trials should be temporarily 
postponed.
 Arrange for research medications to be sent to subjects by the study sponsor if the research 
pharmacy is unavailable.
 Institutional policies on clinical research may be more restrictive and should supersede the 
recommendations contained here.
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Trainees
Although residents and fellows have much to learn from the diagnosis and management of COVID-19, 
there is widespread concern that the risks of exposing trainees to SARS-CoV-2 may outweigh the 
benefits. There is also concern about further reducing the already significant PPE shortages by involving 
trainees in direct patient care. The Accreditation Council for Graduate Medical Education has suspended 
some activities during the COVID-19 pandemic; however, requirements for adequate resources and 
training, adequate supervision, and work hour limitations have not changed.(65,66)
Recommendations
 Ensure adequate resources including PPE appropriate to the clinical setting for all trainees.
 Assign fellows only to participating sites that ensure the safety of patients and fellows.
 Ensure appropriate supervision of trainees working remotely if they are conducting patient care 
activities (telephone/telemedicine visits).
 Change all educational conferences to virtual conferences.
 Consider assigning fellows and other trainees to indirect patient care activities and/or 
telemedicine visits.
 Consider remote supervision of trainees by concurrently monitoring patient care through 
appropriate telecommunication technology.
Conclusion
The COVID-19 pandemic has profoundly strained healthcare resources around the world. Minimizing the 
risk of patient and healthcare worker exposure has been central to our efforts to mitigate the impact of 
the disease on our ability to continue to provide adequate care to our patients. Growing clinical 
experience with COVID-19 evaluation and management has identified subsets of patients who may be at 
higher risk for a more severe disease course. The pandemic has affected patients awaiting liver 
transplantation due to limited transplant center institutional resources and the possibility of donor-
derived infection, which has resulted in longer waiting times. This article provides clinicians caring for 
patients with chronic liver disease with guidance for how to minimize the impact of the COVID-19 
pandemic on their patients’ care. The situation is evolving rapidly and these recommendations will need 
to evolve as well. As we learn more about how the COVID-19 pandemic impacts the care of patients with 
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Disclaimer: This document represents the collective opinion of its authors and approval of the AASLD Governing 
Board as of the date of publication. Its use is voluntary, and it is presented primarily for the purpose of providing 
information to hepatology and liver transplant care providers. This document is not a practice guideline and has 
not been subject to the methodical rigor of a practice guideline. There has not been a systematic evidence review 
as defined by the Health and Medicine Division of the National Academies of Sciences, Engineering, and Medicine 
(formerly the Institute of Medicine), nor is the Grading of Recommendations, Assessment, Development, and 
Evaluation (GRADE) approach utilized. This document does not define a standard of practice or a standard of care. 
It should not be considered as inclusive of all proper treatments or methods of care, nor is it intended to substitute 
for the independent professional judgment of the treating provider. Hospitals, clinics and private practices should 
take into account local standards, practices and environment.
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Figure Legends
Figure 1. Approach to the Patient with COVID-19 and Elevated Serum Liver Biochemistries
Figure 2. Approach to Liver Transplant Organ Offers. 
ICU, intensive care unit; PPE, personal protective equipment.
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Table 1. Challenging Issues in Liver Transplantation During the COVID-19 Pandemic 
 Should we decide who is more in need of limited resources, i.e., COVID-19 patients vs. patients in urgent 
need of liver transplantation? It is impossible to weigh the value of the life of a patient with COVID-19 against 
that of a patient in need of life-saving liver transplantation. We should not compound the pandemic by 
risking the lives of patients in need of liver transplantation and our goal should be to e nsure that an ICU bed 
is available for every patient who requires one. 
 An argument that has been advanced to justify deferring some transplants is a concern about 
immunosuppressing patients during the COVID-19 pandemic. However, it is possible that immunosuppressed 
patients may not be at increased risk for severe COVID-19.(20) Nevertheless, immunosuppressed patients 
have higher viral titers and may be more infectious than immunocompetent individuals.(34) 
 CMS has clarified that transplants fall into Tier 3b and should not be postponed.(32) 
 Other issues to consider in hospitals with a high prevalence of COVID-19 include the risk of nosocomial 
transmission during the transplant admission, difficulty obtaining procedures or other resources when 
complications arise, and limitations on family/caregiver visitation for a postoperative period that often relies 
on the engagement of caregivers. 
 Is there a point at which we need to ration who will receive a liver transplant? If so, we may need to 
prioritize patients who are most likely to die on the waitlist and defer those who can wait longer. 
 These issues are likely to arise in many transplant programs and predominantly center on the need for 
limited ICU beds, ventilators, and blood products. Each program will need to establish its institutional 
capacity to perform liver transplantation and a process for determining whether or not to proceed when an 
organ is available. 
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